Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Flutamide
Drug ID BADD_D00943
Description An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Indications and Usage For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
Marketing Status approved; investigational
ATC Code L02BB01
DrugBank ID DB00499
KEGG ID D00586
MeSH ID D005485
PubChem ID 3397
TTD Drug ID D0Y0SW
NDC Product Code 69097-915; 80725-600; 44657-0048; 60429-272; 12780-4750; 44657-0056; 49884-753; 53104-7536
UNII 76W6J0943E
Synonyms Flutamide | Niftolid | Niftolide | Chimax | Cytamid | Eulexin | Euflex | Drogenil | Eulexine | Fluken | Flulem | Flumid | Fluta 1A Pharma | Fluta-cell | Fluta cell | Flutacell | Fluta-GRY | Fluta GRY | FlutaGRY | Flutamin | Flutandrona | Flutaplex | Flutexin | Fugerel | Grisetin | Novo-Flutamide | Novo Flutamide | NovoFlutamide | Oncosal | PMS-Flutamide | PMS Flutamide | Prostacur | Prostica | Prostogenat | SCH-13521 | SCH 13521 | SCH13521 | Testotard | Apimid | Apo-Flutamide | Apo Flutamide | ApoFlutamide
Chemical Information
Molecular Formula C11H11F3N2O3
CAS Registry Number 13311-84-7
SMILES CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alanine aminotransferase increased13.03.04.005--
Anaemia01.03.02.001--
Anaemia macrocytic14.12.01.002; 01.03.02.002--Not Available
Anxiety19.06.02.002--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Bladder pain20.02.02.001--Not Available
Blood bilirubin increased13.03.04.018--
Blood creatinine13.13.01.020--Not Available
Blood urea abnormal13.13.01.005--Not Available
Blood urea increased13.13.01.006--Not Available
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Breast mass21.05.04.002--Not Available
Breast neoplasm16.10.02.001; 21.05.01.004--Not Available
Breast tenderness21.05.05.004--Not Available
Chromaturia20.02.01.002--
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cystitis20.03.02.002; 11.01.14.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Ecchymosis23.06.01.001; 01.01.03.001; 24.07.06.002--Not Available
Erythema23.03.06.001--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene